scholarly journals Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors’ reply

2019 ◽  
Vol 50 (2) ◽  
pp. 231-232
Author(s):  
Bernhard Scheiner ◽  
Matthias Pinter
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Real World ◽  
Safety Data ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Cell Death Protein ◽  
Targeted Immunotherapy

scholarly journals Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort

2019 ◽  
Vol 49 (10) ◽  
pp. 1323-1333 ◽  
Author(s):  
Bernhard Scheiner ◽  
Martha M. Kirstein ◽  
Florian Hucke ◽  
Fabian Finkelmeier ◽  
Kornelius Schulze ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Real World ◽  
Safety Data ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Cell Death Protein ◽  
Targeted Immunotherapy

PS-138-PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort

2019 ◽  
Vol 70 (1) ◽  
pp. e88-e89
Author(s):  
Bernhard Scheiner ◽  
Martha Kirstein ◽  
Florian Hucke ◽  
Fabian Finkelmeier ◽  
Kornelius Schulze ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Real World ◽  
Safety Data ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
International Multicenter ◽  
Targeted Immunotherapy

scholarly journals Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study

2021 ◽  
Vol 20 ◽  
pp. 153303382110381
Author(s):  
Mei Zhao ◽  
Yiruo Zhang ◽  
Hua Wang ◽  
Pingping Liu ◽  
Jie Da ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Retrospective Study ◽  
Programmed Cell Death ◽  
Disease Control ◽  
Pulmonary Metastases ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Advanced Hcc ◽  
Cell Death Protein

Background: Anti-programmed cell death protein-1 immunotherapy has been approved as a new treatment option for advanced hepatocellular carcinoma (HCC) based on the promising results of several studies. Methods: This retrospective study included 71 patients with advanced HCC treated with anti-programmed cell death protein-1 immunotherapy between June 1, 2017 and September 30, 2020 at the First Affiliated Hospital of Anhui Medical University. Responses to pulmonary metastases were evaluated. Results: The median follow-up duration was 7.73 months (95% confidence interval (CI), 4.48-10.98). Of 71 patients, the overall response rate (ORR) and disease control rate (DCR) were 32% (23/71) and 73% (52/71), respectively. The median progression-free survival (PFS) and overall survival (OS) were 4.90 (95% CI, 2.71-7.09) and 20.23 (95% CI, 6.87-33.59) months, respectively. Forty-two patients had HCC pulmonary metastases, whereas 29 did not have pulmonary metastasis. No significant differences were observed in the ORR (38% [16/42] vs. 24% [7/29], P = 0.22) and DCR (74% [31/42] vs. 72% [21/29], P = 0.90) between groups. In patients with pulmonary metastases, the median disease control duration of pulmonary lesions was significantly longer than extrapulmonary lesions (Not Reached vs. 12.37 months, P = 0.048). Pulmonary metastases were not associated with an increased incidence of adverse events (67% vs. 62%, P = 0.69). Conclusions: Anti-programmed cell death protein-1 immunotherapy showed promising efficacy and safety in patients with advanced HCC, with good responses observed in pulmonary metastases. The mechanism underlying the differences in responses between pulmonary and extrapulmonary metastases requires further investigation.

Abstract 417: Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma

2021 ◽  
Author(s):  
Shaohua Li ◽  
Jie Mei ◽  
Qiaoxuan Wang ◽  
Wei Wei ◽  
Lianghe Lu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Death Protein ◽  
Targeted Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document